| scholarly article | Q13442814 |
| P50 | author | Mark J. Smyth | Q38544864 |
| Dale I Godfrey | Q56957983 | ||
| P2093 | author name string | Yoshihiro Hayakawa | |
| Michele W L Teng | |||
| Jeremy Swann | |||
| Konstantinos Kyparissoudis | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 1582-1587 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer | |
| P478 | volume | 176 |
| Q35512402 | A distinct chemokine axis does not account for enrichment of Foxp3(+) CD4(+) T cells in carcinogen-induced fibrosarcomas. |
| Q38227889 | A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy |
| Q37769443 | A new role for T cells in dampening innate inflammatory responses |
| Q38730855 | A novel method for assaying human regulatory T cell direct suppression of B cell effector function. |
| Q40117289 | A pro-survival role for the intracellular granzyme B inhibitor Serpinb9 in natural killer cells during poxvirus infection. |
| Q36449146 | Activated mouse CD4+Foxp3− T cells facilitate melanoma metastasis via Qa-1-dependent suppression of NK-cell cytotoxicity |
| Q41085383 | Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection |
| Q28744029 | Activation of Cytotoxic and Regulatory Functions of NK Cells by Sindbis Viral Vectors |
| Q64998492 | Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. |
| Q33912853 | Adaptive control of innate immunity |
| Q35269067 | Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression |
| Q39969906 | Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10. |
| Q84086506 | Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency |
| Q50320917 | An attempt to induce an immunomodulatory effect in rowers with spirulina extract. |
| Q36916476 | Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells |
| Q45857655 | Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-λ2 or IL-29/IFN-λ1. |
| Q27000514 | Antibody-based immunotherapy for ovarian cancer: where are we at? |
| Q42185296 | Are we ready for the use of foxp3(+) regulatory T cells for immunodiagnosis and immunotherapy in kidney transplantation? |
| Q85895064 | Associations Between Infiltrating Lymphocyte Subsets and Hepatocellular Carcinoma |
| Q38151057 | At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias |
| Q48834589 | Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D. |
| Q36546883 | Autologous stem cell transplant recipients tolerate haploidentical related‐donor natural killer cell–enriched infusions |
| Q43418649 | B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion |
| Q39134212 | Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy |
| Q37234615 | Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells |
| Q37346143 | Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. |
| Q34091467 | CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice |
| Q34624101 | CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients |
| Q37317928 | CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus |
| Q41677003 | CD4+CD25+ Regulatory T Cells Inhibit Natural Killer Cell Hepatocytotoxicity of Hepatitis B Virus Transgenic Mice via Membrane-Bound TGF-β and OX40. |
| Q36915014 | CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer |
| Q36600237 | CD4+CD25+ regulatory T cell therapy for the induction of donor-specific clinical transplantation tolerance |
| Q37754524 | CD4+CD25+ regulatory T-cell therapy |
| Q64976727 | CD4+CD25+Foxp3+ regulatory T cells suppress NKG2D-mediated NK cell cytotoxicity in peripheral blood. |
| Q30445860 | CD86 is an activation receptor for NK cell cytotoxicity against tumor cells |
| Q35674757 | CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis |
| Q37315667 | Can NK cells be a therapeutic target in human cancer? |
| Q38114594 | Cellular therapy of cancer with natural killer cells—where do we stand? |
| Q38102783 | Clinical application of regulatory T cells in type 1 diabetes. |
| Q36696647 | Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy |
| Q37327064 | Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses |
| Q26781260 | Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress |
| Q37268005 | Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation |
| Q37771915 | Cytokine regulation of natural killer cell effector functions |
| Q61903522 | Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity |
| Q36764903 | Dendritic cell-based active specific immunotherapy for malignant glioma |
| Q40176032 | Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma |
| Q33688225 | Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia |
| Q40832649 | Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer |
| Q82849384 | Do adaptive immune cells suppress or activate innate immunity? |
| Q35632112 | Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study |
| Q36422943 | Effective modulation of CD4+CD25+high regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2 |
| Q37038163 | Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. |
| Q36486882 | Emerging possibilities in the development and function of regulatory T cells |
| Q28069422 | Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis |
| Q40039638 | Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells |
| Q36471068 | Epigenetic regulation of immune escape genes in cancer |
| Q93081879 | Evaluation of quantitative changes in regulatory T cells in peripheral blood of kidney transplant recipients with skin cancer after conversion to mTOR inhibitors |
| Q56899556 | Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner |
| Q29614300 | Functions of natural killer cells |
| Q35208414 | Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity |
| Q39476748 | Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells |
| Q34651540 | IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells |
| Q82292256 | Identification of a unique double-negative regulatory T-cell population |
| Q26991724 | Immune cell promotion of metastasis |
| Q37993738 | Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD |
| Q35050810 | Immune profiling and cancer post transplantation |
| Q35719883 | Immunosurveillance and therapy of multiple myeloma are CD226 dependent |
| Q35952087 | Impact of dietary components on NK and Treg cell function for cancer prevention |
| Q43263198 | Impairment in cytotoxicity and expression of NK cell- activating receptors on human NK cells following exposure to asbestos fibers |
| Q91708036 | Impairment of NKG2D-Mediated Tumor Immunity by TGF-β |
| Q34382955 | Induction of Immune Tolerance to a Therapeutic Protein by Intrathymic Gene Delivery |
| Q91759706 | Infectivity of GII.4 human norovirus does not differ between T-B-NK+ severe combined immunodeficiency (SCID) and non-SCID gnotobiotic pigs, implicating the role of NK cells in mediation of human norovirus infection |
| Q37000445 | Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs |
| Q46385904 | Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells |
| Q34550147 | Innate immune recognition and suppression of tumors |
| Q28068375 | Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells |
| Q93018628 | Integration analysis for novel lncRNA markers predicting tumor recurrence in human colon adenocarcinoma |
| Q27008625 | Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy |
| Q38240762 | Interactions between innate and adaptive lymphocytes. |
| Q41897122 | Interleukin-17D mediates tumor rejection through recruitment of natural killer cells |
| Q37930988 | Intestinal inflammation and colorectal cancer: a double-edged sword? |
| Q37996368 | Investigation of NK cell function and their modulation in different malignancies. |
| Q43865719 | Leveraging natural killer cells for cancer immunotherapy |
| Q35224136 | Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration |
| Q52353493 | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. |
| Q36608731 | Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer |
| Q64259394 | Memory NK Cell Features Exploitable in Anticancer Immunotherapy |
| Q34847859 | Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS- regulatory T cells. |
| Q39281058 | MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. |
| Q50671091 | Molecular Mechanisms of Regulatory T Cell Development and Suppressive Function |
| Q42200876 | Mouse cytomegalovirus infection overrules T regulatory cell suppression on natural killer cells. |
| Q26823251 | Myeloid Suppressor Cells and Immune Modulation in Lung Cancer |
| Q83402971 | NK Cell Adoptive Transfer Combined with Ontak-Mediated Regulatory T Cell Elimination Induces Effective Adaptive Antitumor Immune Responses |
| Q40048056 | NK Cell Effector Functions Regulation by Modulating nTreg Cell Population During Progressive Growth of Dalton's Lymphoma in Mice |
| Q61811846 | NK Cell-Based Immunotherapy in Cancer Metastasis |
| Q37101325 | NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy |
| Q37315670 | NK cells and Treg cells: a fascinating dance cheek to cheek |
| Q39236283 | NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short‐term IL‐2 activation |
| Q38036202 | NK cells: key to success of DC-based cancer vaccines? |
| Q35915642 | NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment |
| Q39196323 | NKG2D ligand expression in pediatric brain tumors. |
| Q27014888 | NKG2D ligands as therapeutic targets |
| Q37287179 | NKG2D ligands in tumor immunity |
| Q38194944 | NKG2D signaling in cancer immunosurveillance |
| Q87354087 | Nanoparticle immunotherapy: Combo combat |
| Q37959322 | Natural Killer (NK) Cells in Antibacterial Innate Immunity: Angels or Devils? |
| Q33754724 | Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients |
| Q37996816 | Natural killer cell immune escape in acute myeloid leukemia. |
| Q38169654 | Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL. |
| Q37866598 | Natural killer cells and solid tumors. |
| Q37524719 | Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses |
| Q56898695 | Neem Leaf Glycoprotein Inhibits CD4 + CD25 + Foxp3 + Tregs to Restrict Murine Tumor Growth |
| Q27001081 | Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses |
| Q21560837 | Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth |
| Q36127288 | Nuclear receptors as modulators of the tumor microenvironment |
| Q48032304 | Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells |
| Q42149012 | Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells |
| Q36652177 | Physiological roles of murine DAP10 adapter protein in tumor immunity and autoimmunity |
| Q55401142 | Polysaccharides from Chinese Herbal Lycium barbarum Induced Systemic and Local Immune Responses in H22 Tumor-Bearing Mice. |
| Q37287156 | Positive and negative influences of regulatory T cells on tumour immunity. |
| Q54278437 | Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand |
| Q37379967 | Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention |
| Q33769545 | Prediction of antiviral efficacy in patients with chronic hepatitis C by changes in forkhead box protein 3 levels |
| Q36057599 | Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells |
| Q46113809 | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation |
| Q33713903 | Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity |
| Q37256962 | Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells |
| Q43166710 | Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells. |
| Q26991447 | Regulatory T cell: a protection for tumour cells |
| Q45243164 | Regulatory T cells and NK cells in cancer patients |
| Q34651528 | Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. |
| Q38020963 | Regulatory T cells in the central nervous system |
| Q37691776 | Regulatory T cells in transplantation: does extracellular adenosine triphosphate metabolism through CD39 play a crucial role? |
| Q38640091 | Regulatory T cells inhibit CD34+ cell differentiation into NK cells by blocking their proliferation. |
| Q39418860 | Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. |
| Q28475223 | Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta |
| Q35384216 | Regulatory T-cell Trafficking: From Thymic Development to Tumor-Induced Immune Suppression |
| Q39210022 | Role of Distinct Natural Killer Cell Subsets in Anticancer Response |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q92317164 | STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer |
| Q37281838 | Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy |
| Q38067641 | Shaping of NK cell responses by the tumor microenvironment |
| Q59255570 | Some latest achievements in immunology research |
| Q26996034 | Subsets of human natural killer cells and their regulatory effects |
| Q34600272 | Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells |
| Q36907905 | T cell regulation of natural killer cells |
| Q28263622 | TGF-beta: a mobile purveyor of immune privilege |
| Q39155158 | TGF-β Family Signaling in Tumor Suppression and Cancer Progression. |
| Q34205905 | TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence |
| Q38005176 | Targeting NKG2D in tumor surveillance |
| Q30413623 | Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer |
| Q38829849 | Targeting natural killer cells in cancer immunotherapy |
| Q36975757 | The 'kiss of death' by dendritic cells to cancer cells |
| Q58700856 | The Cytotoxic Activity of Natural Killer Cells Is Suppressed by IL-10 Regulatory T Cells During Acute Retroviral Infection |
| Q57166654 | The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy |
| Q26774875 | The Role of Immune Cells in Chronic HBV Infection |
| Q36101238 | The Role of Regulatory T Cells in Mesothelioma. |
| Q57816901 | The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity |
| Q33608606 | The Treg/Th17 paradigm in lung cancer |
| Q34343645 | The Tumor Microenvironment in Colorectal Carcinogenesis |
| Q36694921 | The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity |
| Q37638179 | The natural killer cell: a further innate mediator of gouty inflammation? |
| Q58211845 | The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2α but not HIF-1α |
| Q36652214 | The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression |
| Q37452411 | The role of tregs in glioma-mediated immunosuppression: potential target for intervention. |
| Q28261890 | The roles of Galectin-3 in autoimmunity and tumor progression |
| Q84192939 | The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN |
| Q39726876 | Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance |
| Q33712568 | Transforming growth factor beta (TGF-beta) and inflammation in cancer |
| Q39254820 | Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells |
| Q52373701 | Treg cells limit IFN-γ production to control macrophage accrual and phenotype during skeletal muscle regeneration |
| Q33330270 | Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials |
| Q40113311 | Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. |
| Q36997144 | Tumor stress, cell death and the ensuing immune response. |
| Q36516410 | Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer |
| Q89622537 | Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment |
| Q40047650 | Use of natural killer cells as immunotherapy for leukaemia. |
| Q37037667 | Virus-based immunotherapy of cancer: what do we know and where are we going? |
| Q41114263 | Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche Establishment |
Search more.